Loading…
Loading…
AMST does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for AMST and 80,000+ other tickers.
See exactly how AMST's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for AMST and 80,000+ other tickers.
Amesite Inc. is a Detroit, Michigan-based company, founded in 2017, that specializes in developing AI-powered online learning platforms and course content. Operating across the United States, the firm delivers digital educational solutions by leveraging advanced machine learning to provide highly personalized learning experiences on a broad scale. Their diverse clientele includes corporate entities, higher education institutions, K-12 school systems, and non-profit organizations.
Amesite (AMST) ripped 250% in premarket trading Tuesday after the AI software company secured a new enterprise customer representing an approximately 2,700-pati
Amesite shares jumped 90.82% after hours after announcing a major enterprise deployment and reporting strong year-over-year revenue growth.
Enterprise Deployment Validates AI-Native Infrastructure Strategy and Proves Scalable, Cost-Efficient Execution in Non-Acute Care Enterprise Deployment Validates AI-Native Infrastructure Strategy and Proves Scalable, Cost-Efficient Execution in Non-Acute Care
$2.6 million upfront with up to approximately $5.2 million of potential aggregate proceeds upon the exercise in full of warrants $2.6 million upfront with up to approximately $5.2 million of potential aggregate proceeds upon the exercise in full of warrants
DETROIT, April 28, 2026 (GLOBE NEWSWIRE) -- Amesite Inc. (Nasdaq: AMST), developer of the AI‑native NurseMagic™ platform and EMR for non‑acute care, today announced that it has entered into definitive agreements with certain of its officers and directors, including Dr. Ann Marie Sastry, Ph.D, its Chairman and CEO, and George Parmer, a member of its board of directors, for the purchase and sale of an aggregate of 418,118 shares of its common stock, Series A-1 warrants to purchase an aggregate up to 418,118 shares of the Company's common stock and Series A-2 warrants to purchase an aggregate up to 418,118 shares of the Company's common stock at a purchase price of $1.435 per share and accompanying warrants. The private placement follows the Company's recently announced concurrent registered direct offering and private placement, priced at-the-market under Nasdaq rules, which is expected to result in aggregate gross proceeds to the Company of approximately $2 million, before deducting placement agent fees and other offering expenses.